PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Geert R. D'Haens  ¹     Omoniyi J. Adedokun  ²     Silvio Danese  ³     Severine Vermeire  ⁴     Julian Panés  ⁵     Axel Dignass  ⁶     Fernando Magro  ⁷     Maciek Nazar  ⁸     Manuela Le Bars  ⁹     Marjolein Lahaye  ¹⁰     Lioudmila Ni  ¹¹     Daniel R. Gaya  ¹²     Laurent Peyrin-Biroulet  ^13    
1 Amsterdam University Medical Centers, Amsterdam, Netherlands
² Janssen Research & Development, LLC., Spring House, United States
³ Humanitas University, Milan, Italy
⁴ University Hospitals Leuven, Leuven, Belgium
⁵ Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
⁶ Agaplesion Markus Hospital, Frankfurt/Main, Germany
⁷ Institute for Molecular and Cell Biology, Faculty of Medicine University of Porto, Porto, Portugal
⁸ Janssen-Cilag Polska Sp. z o.o., Warsaw, Poland
⁹ Janssen-Cilag, Issy-les-Moulineaux, France
¹⁰ Janssen-Cilag BV, Breda, Netherlands
¹¹ Janssen-Cilag Russia, Moscow, Russian Federation
¹² Glasgow Royal Infirmary, Glasgow, United Kingdom
¹³ University Hospital of Nancy, University of Lorraine, Houdemont, France

Topic
Gut Microbiota, IBD, Immunology

Session
IBD: Drug monitoring

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)